ArticleInterdisciplinary cardiovascular and thoracic surgery2023
Segmentectomy for cancer control in radiologically pure-solid clinical stage IA3 lung cancer.
Article in Interdisciplinary cardiovascular and thoracic surgery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 13 citations in OpenAlex.
- Comparative Outcomes of Segmentectomy Versus Lobectomy for Solid Dominant Lung Cancer with a Tumor Diameter of 2-3 cm.Journal of clinical medicine · 2026Article
- Impact of pathologically confirmed inner lung tumors on nodal upstaging and feasibility of segmentectomy versus lobectomy.JTCVS open · 2026Article
- Risk factors of up-Stage and lymph node metastasis for clinical stage IA3 non-small cell lung cancer.Journal of thoracic disease · 2025Article
- Article
- Segmentectomy is associated with worse disease-free survival compared to lobectomy in patients with stage IA3 non-small cell lung cancer.Langenbeck's archives of surgery · 2025Article
- Proposal for novel definition of radiologically less-invasive clinical stage IA solid predominant lung adenocarcinoma using the maximum standardized uptake value.General thoracic and cardiovascular surgery · 2025Article
- Segmentectomy versus lobectomy for centrally located small-sized and radiologically pure-solid non-small cell lung cancer.JTCVS open · 2025Article
- Is segmentectomy potentially adequate for clinical stage IA3 non-small cell lung cancer.Interdisciplinary cardiovascular and thoracic surgery · 2025Article
- Comparison of segmentectomy and wedge resection for cT1cN0M0 non-small cell lung cancer.General thoracic and cardiovascular surgery · 2025Article
- Loco-regional relapse pattern and timing after segmentectomy in patients with c-IA non-small cell lung cancer.Journal of thoracic disease · 2024Article
- Distinct impacts of radiological appearance on lymph node metastasis and prognosis based on solid size in clinical T1 non-small cell lung cancer.Respiratory research · 2024Article
- Segmentectomy for stage IA3 tumours: just another day in clinic.Interdisciplinary cardiovascular and thoracic surgery · 2023Article
- Segmentectomy for patients with early-stage pure-solid non-small cell lung cancer.Frontiers in oncology · 2023Review
Corrections and comments
- Commented on by
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to compare cancer control after segmentectomy and lobectomy in patients with radiologically pure-solid clinical stage IA3 non-small-cell lung cancer (NSCLC).
methodsPatients with radiologically pure-solid clinical stage IA3 NSCLC who underwent lobectomy or segmentectomy at 3 institutions between 2010 and 2019 were identified. We estimated propensity scores to adjust for confounding variables regarding tumour malignancy, including age, sex, smoking history, tumour size, maximum standardized uptake value on 18F-fluorodeoxyglucose positron emission tomography, lymph node dissection, histological type and lymphatic, vascular and pleural invasion. Cumulative incidence of recurrence (CIR) was evaluated as a primary end point.
resultsAmong 412 patients, postoperative recurrence occurred in 7 of 44 patients (15.9%) undergoing segmentectomy, and 71 of 368 patients (19.3%) undergoing lobectomy. CIR was comparable between patients undergoing segmentectomy (5-year rate, 21.9%) and those undergoing lobectomy (5-year rate, 20.8%; P = 0.88). Locoregional recurrence did not differ between patients undergoing segmentectomy (6.8%) and those undergoing lobectomy (9.0%). In multivariable analysis, segmentectomy (versus lobectomy) was not identified as an independent prognostic factor for CIR (hazard ratio, 1.045; 95% confidence interval, 0.475-2.298; P = 0.91). In propensity score matching of 40 pairs, CIR was not significantly different between patients undergoing segmentectomy (5-year rate, 20.7%) and those undergoing lobectomy (5-year rate, 18.4%; P = 0.81).
conclusionsCancer control may be comparable between segmentectomy and lobectomy in patients with radiologically pure-solid clinical stage IA3 NSCLC. Further studies are warranted to clarify the survival benefits of segmentectomy in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.